{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:14:22Z","timestamp":1790180062471,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1097\/spc.0b013e32830baea9","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T16:54:54Z","timestamp":1236272094000},"page":"218-222","source":"Crossref","is-referenced-by-count":67,"title":["Cathepsin K inhibitors as treatment of bone metastasis"],"prefix":"10.1097","volume":"2","author":[{"given":"C\u00e9line","family":"Le Gall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Bonnelye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Cl\u00e9zardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210126","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10585-007-9112-8","article-title":"Bone metastasis: pathogenesis and therapeutic implications","volume":"24","author":"Clezardin","year":"2007","journal-title":"Clin Exp Metastasis"},{"key":"R2-12-20210126","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrc1949","article-title":"Cysteine cathepsins: multifunctional enzymes in cancer","volume":"6","author":"Mohamed","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"R3-12-20210126","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2174\/138161207779313542","article-title":"Emerging roles of cysteine cathepsins in disease and their potential as drug targets","volume":"13","author":"Vasiljeva","year":"2007","journal-title":"Curr Pharm Design"},{"key":"R4-12-20210126","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1126\/science.1150110","article-title":"Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis","volume":"319","author":"Asagiri","year":"2008","journal-title":"Science"},{"key":"R5-12-20210126","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1371\/journal.pone.0000683","article-title":"Cathepsin K null mice show reduced adiposity during the rapid accumulation of fat stores","volume":"2","author":"Funicello","year":"2007","journal-title":"PLoS One"},{"key":"R6-12-20210126","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/ncb1623","article-title":"Cathepsin L activity controls adipogenesis and glucose tolerance","volume":"9","author":"Yang","year":"2007","journal-title":"Nat Cell Biol"},{"key":"R7-12-20210126","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","article-title":"Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency","volume":"273","author":"Gelb","year":"1996","journal-title":"Science"},{"key":"R8-12-20210126","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1073\/pnas.95.23.13453","article-title":"Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice","volume":"95","author":"Saftig","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"R9-12-20210126","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1359\/jbmr.2001.16.8.1444","article-title":"Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K","volume":"16","author":"Kiviranta","year":"2001","journal-title":"J Bone Min Res"},{"key":"R10-12-20210126","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1359\/jbmr.060614","article-title":"Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone","volume":"21","author":"Everts","year":"2006","journal-title":"J Bone Min Res"},{"key":"R11-12-20210126","first-page":"5386","article-title":"The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma","volume":"57","author":"Littlewood-Evans","year":"1997","journal-title":"Cancer Res"},{"key":"R12-12-20210126","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1359\/jbmr.2003.18.2.222","article-title":"Cathepsin K mRNA and protein expression in prostate cancer progression","volume":"18","author":"Brubaker","year":"2003","journal-title":"J Bone Min Res"},{"key":"R13-12-20210126","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1158\/0008-5472.CAN-06-3940","article-title":"A cathepsin K inhibitor reduces breast cancer-induced osteolysis and skeletal tumor burden","volume":"67","author":"Le Gall","year":"2007","journal-title":"Cancer Res"},{"key":"R14-12-20210126","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-006-9279-8","article-title":"Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells","volume":"101","author":"Bellahc\u00e8ne","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"R16-12-20210126","first-page":"619","article-title":"Recent developments in cathepsin K inhibitor design","volume":"8","author":"Grabowska","year":"2005","journal-title":"Curr Opin Drug Discov Dev"},{"key":"R17-12-20210126","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/sj.clpt.6100450","article-title":"Cathepsin K inhibitors: a novel target for osteoporosis therapy","volume":"83","author":"Stoch","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R18-12-20210126","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.bmcl.2007.12.047","article-title":"The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K","volume":"18","author":"Gauthier","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"R19-12-20210126","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.bone.2007.01.010","article-title":"Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice","volume":"40","author":"Xiang","year":"2007","journal-title":"Bone"},{"key":"R20-12-20210126","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bone.2007.09.044","article-title":"Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts","volume":"42","author":"Fuller","year":"2008","journal-title":"Bone"},{"key":"R21-12-20210126","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1124\/mol.107.039511","article-title":"Effect of cathepsin K inhibitor basicity on in vivo off-target activities","volume":"73","author":"Desmarais","year":"2008","journal-title":"Mol Pharmacol"},{"key":"R22-12-20210126","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2006.07.015","article-title":"A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vivo and in an acute model of elevated bone turnover in vivo in monkeys","volume":"40","author":"Kumar","year":"2007","journal-title":"Bone"},{"key":"R24-12-20210126","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature04524","article-title":"Regulation of cancer cell migration and bone metastasis by RANKL","volume":"440","author":"Jones","year":"2006","journal-title":"Nature"},{"key":"R25-12-20210126","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease","volume":"107","author":"Dewar","year":"2006","journal-title":"Blood"},{"key":"R26-12-20210126","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1358\/dot.2008.44.1.1178467","article-title":"Denosumab: RANKL inhibition in the management of bone loss","volume":"44","author":"Hamdy","year":"2008","journal-title":"Drugs Today"},{"key":"R27-12-20210126","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1158\/0008-5472.CAN-04-3601","article-title":"Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer","volume":"65","author":"Kim","year":"2005","journal-title":"Cancer Res"}],"container-title":["Current Opinion in Supportive & Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/SPC.0b013e32830baea9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:40:47Z","timestamp":1786038047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01263393-200809000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0b013e32830baea9","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}